Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
25,125
archived clinical trials in
Diabetes

A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes
The Effect of LY2189265 on Blood Pressure and Heart Rate, as Assessed by Ambulatory Blood Pressure Monitoring, in Patients With Type 2 Diabetes Mellitus
Status: Archived
Clinical Research Facility
mi
from
Hazard, KY
A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes
The Effect of LY2189265 on Blood Pressure and Heart Rate, as Assessed by Ambulatory Blood Pressure Monitoring, in Patients With Type 2 Diabetes Mellitus
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Hazard, KY
A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes
The Effect of LY2189265 on Blood Pressure and Heart Rate, as Assessed by Ambulatory Blood Pressure Monitoring, in Patients With Type 2 Diabetes Mellitus
Status: Archived
Clinical Research Facility
mi
from
Alexandria, LA
A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes
The Effect of LY2189265 on Blood Pressure and Heart Rate, as Assessed by Ambulatory Blood Pressure Monitoring, in Patients With Type 2 Diabetes Mellitus
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Alexandria, LA
A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes
The Effect of LY2189265 on Blood Pressure and Heart Rate, as Assessed by Ambulatory Blood Pressure Monitoring, in Patients With Type 2 Diabetes Mellitus
Status: Archived
Clinical Research Facility
mi
from
Scarborough, ME
A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes
The Effect of LY2189265 on Blood Pressure and Heart Rate, as Assessed by Ambulatory Blood Pressure Monitoring, in Patients With Type 2 Diabetes Mellitus
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Scarborough, ME
A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes
The Effect of LY2189265 on Blood Pressure and Heart Rate, as Assessed by Ambulatory Blood Pressure Monitoring, in Patients With Type 2 Diabetes Mellitus
Status: Archived
Clinical Research Facility
mi
from
Bethesda, MD
A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes
The Effect of LY2189265 on Blood Pressure and Heart Rate, as Assessed by Ambulatory Blood Pressure Monitoring, in Patients With Type 2 Diabetes Mellitus
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Bethesda, MD
A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes
The Effect of LY2189265 on Blood Pressure and Heart Rate, as Assessed by Ambulatory Blood Pressure Monitoring, in Patients With Type 2 Diabetes Mellitus
Status: Archived
Clinical Research Facility
mi
from
Boston, MA
A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes
The Effect of LY2189265 on Blood Pressure and Heart Rate, as Assessed by Ambulatory Blood Pressure Monitoring, in Patients With Type 2 Diabetes Mellitus
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Boston, MA
A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes
The Effect of LY2189265 on Blood Pressure and Heart Rate, as Assessed by Ambulatory Blood Pressure Monitoring, in Patients With Type 2 Diabetes Mellitus
Status: Archived
Clinical Research Facility
mi
from
Lansing, MI
A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes
The Effect of LY2189265 on Blood Pressure and Heart Rate, as Assessed by Ambulatory Blood Pressure Monitoring, in Patients With Type 2 Diabetes Mellitus
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Lansing, MI
A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes
The Effect of LY2189265 on Blood Pressure and Heart Rate, as Assessed by Ambulatory Blood Pressure Monitoring, in Patients With Type 2 Diabetes Mellitus
Status: Archived
Clinical Research Facility
mi
from
Picayune, MS
A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes
The Effect of LY2189265 on Blood Pressure and Heart Rate, as Assessed by Ambulatory Blood Pressure Monitoring, in Patients With Type 2 Diabetes Mellitus
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Picayune, MS
A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes
The Effect of LY2189265 on Blood Pressure and Heart Rate, as Assessed by Ambulatory Blood Pressure Monitoring, in Patients With Type 2 Diabetes Mellitus
Status: Archived
Hartford Hospital- The Institute of Living
mi
from
Hartford, CT
A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes
The Effect of LY2189265 on Blood Pressure and Heart Rate, as Assessed by Ambulatory Blood Pressure Monitoring, in Patients With Type 2 Diabetes Mellitus
Status: Archived
Updated: 1/1/1970
Hartford Hospital- The Institute of Living
mi
from
Hartford, CT
A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes
The Effect of LY2189265 on Blood Pressure and Heart Rate, as Assessed by Ambulatory Blood Pressure Monitoring, in Patients With Type 2 Diabetes Mellitus
Status: Archived
Clinical Research Facility
mi
from
Missoula, MT
A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes
The Effect of LY2189265 on Blood Pressure and Heart Rate, as Assessed by Ambulatory Blood Pressure Monitoring, in Patients With Type 2 Diabetes Mellitus
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Missoula, MT
A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes
The Effect of LY2189265 on Blood Pressure and Heart Rate, as Assessed by Ambulatory Blood Pressure Monitoring, in Patients With Type 2 Diabetes Mellitus
Status: Archived
Clinical Research Facility
mi
from
Omaha, NE
A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes
The Effect of LY2189265 on Blood Pressure and Heart Rate, as Assessed by Ambulatory Blood Pressure Monitoring, in Patients With Type 2 Diabetes Mellitus
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Omaha, NE
A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes
The Effect of LY2189265 on Blood Pressure and Heart Rate, as Assessed by Ambulatory Blood Pressure Monitoring, in Patients With Type 2 Diabetes Mellitus
Status: Archived
Clinical Research Facility
mi
from
Santa Fe, NM
A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes
The Effect of LY2189265 on Blood Pressure and Heart Rate, as Assessed by Ambulatory Blood Pressure Monitoring, in Patients With Type 2 Diabetes Mellitus
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Santa Fe, NM
A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes
The Effect of LY2189265 on Blood Pressure and Heart Rate, as Assessed by Ambulatory Blood Pressure Monitoring, in Patients With Type 2 Diabetes Mellitus
Status: Archived
Clinical Research Facility
mi
from
Brooklyn, NY
A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes
The Effect of LY2189265 on Blood Pressure and Heart Rate, as Assessed by Ambulatory Blood Pressure Monitoring, in Patients With Type 2 Diabetes Mellitus
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Brooklyn, NY
A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes
The Effect of LY2189265 on Blood Pressure and Heart Rate, as Assessed by Ambulatory Blood Pressure Monitoring, in Patients With Type 2 Diabetes Mellitus
Status: Archived
Clinical Research Facility
mi
from
Cincinnati, OH
A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes
The Effect of LY2189265 on Blood Pressure and Heart Rate, as Assessed by Ambulatory Blood Pressure Monitoring, in Patients With Type 2 Diabetes Mellitus
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Cincinnati, OH
A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes
The Effect of LY2189265 on Blood Pressure and Heart Rate, as Assessed by Ambulatory Blood Pressure Monitoring, in Patients With Type 2 Diabetes Mellitus
Status: Archived
New York Methodist Hospital
mi
from
Brooklyn, NY
A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes
The Effect of LY2189265 on Blood Pressure and Heart Rate, as Assessed by Ambulatory Blood Pressure Monitoring, in Patients With Type 2 Diabetes Mellitus
Status: Archived
Updated: 1/1/1970
New York Methodist Hospital
mi
from
Brooklyn, NY
A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes
The Effect of LY2189265 on Blood Pressure and Heart Rate, as Assessed by Ambulatory Blood Pressure Monitoring, in Patients With Type 2 Diabetes Mellitus
Status: Archived
Clinical Research Facility
mi
from
Fort Worth, TX
A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes
The Effect of LY2189265 on Blood Pressure and Heart Rate, as Assessed by Ambulatory Blood Pressure Monitoring, in Patients With Type 2 Diabetes Mellitus
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Fort Worth, TX
A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes
The Effect of LY2189265 on Blood Pressure and Heart Rate, as Assessed by Ambulatory Blood Pressure Monitoring, in Patients With Type 2 Diabetes Mellitus
Status: Archived
Clinical Research Facility
mi
from
American Fork, UT
A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes
The Effect of LY2189265 on Blood Pressure and Heart Rate, as Assessed by Ambulatory Blood Pressure Monitoring, in Patients With Type 2 Diabetes Mellitus
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
American Fork, UT
A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes
The Effect of LY2189265 on Blood Pressure and Heart Rate, as Assessed by Ambulatory Blood Pressure Monitoring, in Patients With Type 2 Diabetes Mellitus
Status: Archived
Clinical Research Facility
mi
from
Seattle, WA
A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes
The Effect of LY2189265 on Blood Pressure and Heart Rate, as Assessed by Ambulatory Blood Pressure Monitoring, in Patients With Type 2 Diabetes Mellitus
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Seattle, WA
Pharmacodynamic and Pharmacokinetic Variability of a Basal Insulin (0000-168)
A Two-Part Clinical Trial to Assess Pharmacodynamic and Pharmacokinetic Variability of a Basal Insulin
Status: Archived
Clinical Research Facility
mi
from
Dallas, TX
Pharmacodynamic and Pharmacokinetic Variability of a Basal Insulin (0000-168)
A Two-Part Clinical Trial to Assess Pharmacodynamic and Pharmacokinetic Variability of a Basal Insulin
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Dallas, TX
Louisiana State University Health Care Services Division (LSUHSCD) Tele-Health Projects: Weight Loss in Chronic Disease Patient Population
Louisiana State University Health Care Services Division Tele-Health Projects: Weight Loss in Chronic Disease Patient Population
Status: Archived
Earl K. Long Medical Center
mi
from
Baton Rouge, LA
Louisiana State University Health Care Services Division (LSUHSCD) Tele-Health Projects: Weight Loss in Chronic Disease Patient Population
Louisiana State University Health Care Services Division Tele-Health Projects: Weight Loss in Chronic Disease Patient Population
Status: Archived
Updated: 1/1/1970
Earl K. Long Medical Center
mi
from
Baton Rouge, LA
Louisiana State University Health Care Services Division (LSUHSCD) Tele-Health Projects: Weight Loss in Chronic Disease Patient Population
Louisiana State University Health Care Services Division Tele-Health Projects: Weight Loss in Chronic Disease Patient Population
Status: Archived
Leonard J. Chabert Medical Center
mi
from
Houma, LA
Louisiana State University Health Care Services Division (LSUHSCD) Tele-Health Projects: Weight Loss in Chronic Disease Patient Population
Louisiana State University Health Care Services Division Tele-Health Projects: Weight Loss in Chronic Disease Patient Population
Status: Archived
Updated: 1/1/1970
Leonard J. Chabert Medical Center
mi
from
Houma, LA
Louisiana State University Health Care Services Division (LSUHSCD) Tele-Health Projects: Weight Loss in Chronic Disease Patient Population
Louisiana State University Health Care Services Division Tele-Health Projects: Weight Loss in Chronic Disease Patient Population
Status: Archived
WO Moss Regional Medical Center
mi
from
Lake Charles, LA
Louisiana State University Health Care Services Division (LSUHSCD) Tele-Health Projects: Weight Loss in Chronic Disease Patient Population
Louisiana State University Health Care Services Division Tele-Health Projects: Weight Loss in Chronic Disease Patient Population
Status: Archived
Updated: 1/1/1970
WO Moss Regional Medical Center
mi
from
Lake Charles, LA
Combination Therapy With Sitagliptin and Lansoprazole to Restore Pancreatic Beta Cell Function in Recent-Onset Type 1 Diabetes
Combination Therapy With Sitagliptin (DPP 4 Inhibitor) and Lansoprazole (PPI) Inhibitor) to Restore Pancreatic Beta Cell Function in Recent-Onset Type 1 Diabetes
Status: Archived
Sanford Research/USD
mi
from
Sioux Falls, SD
Combination Therapy With Sitagliptin and Lansoprazole to Restore Pancreatic Beta Cell Function in Recent-Onset Type 1 Diabetes
Combination Therapy With Sitagliptin (DPP 4 Inhibitor) and Lansoprazole (PPI) Inhibitor) to Restore Pancreatic Beta Cell Function in Recent-Onset Type 1 Diabetes
Status: Archived
Updated: 1/1/1970
Sanford Research/USD
mi
from
Sioux Falls, SD
Diabetes Prevention in Women With a Recent History of Gestational Diabetes Mellitus (GDM)
Diabetes Prevention in Women With a Recent History of Gestational Diabetes Mellitus (GDM)
Status: Archived
Brigham & Women's Hospital Women's Health Center
mi
from
Chestnut Hill, MA
Diabetes Prevention in Women With a Recent History of Gestational Diabetes Mellitus (GDM)
Diabetes Prevention in Women With a Recent History of Gestational Diabetes Mellitus (GDM)
Status: Archived
Updated: 1/1/1970
Brigham & Women's Hospital Women's Health Center
mi
from
Chestnut Hill, MA
Efficacy and Safety Study With BI 10773 vs. Placebo as add-on to Metformin or Metformin Plus Sulfonyurea Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orallly, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Suflonylurea
Status: Archived
Boehringer Ingelheim Investigational Site
mi
from
Birmingham, AL
Efficacy and Safety Study With BI 10773 vs. Placebo as add-on to Metformin or Metformin Plus Sulfonyurea Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orallly, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Suflonylurea
Status: Archived
Updated: 1/1/1970
Boehringer Ingelheim Investigational Site
mi
from
Birmingham, AL
Efficacy and Safety Study With BI 10773 vs. Placebo as add-on to Metformin or Metformin Plus Sulfonyurea Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orallly, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Suflonylurea
Status: Archived
205.452.01317 Boehringer Ingelheim Investigational Site
mi
from
Mesa, AZ
Efficacy and Safety Study With BI 10773 vs. Placebo as add-on to Metformin or Metformin Plus Sulfonyurea Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orallly, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Suflonylurea
Status: Archived
Updated: 1/1/1970
205.452.01317 Boehringer Ingelheim Investigational Site
mi
from
Mesa, AZ
Efficacy and Safety Study With BI 10773 vs. Placebo as add-on to Metformin or Metformin Plus Sulfonyurea Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orallly, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Suflonylurea
Status: Archived
9.197.001 Boehringer Ingelheim Investigational Site
mi
from
Tempe, AZ
Efficacy and Safety Study With BI 10773 vs. Placebo as add-on to Metformin or Metformin Plus Sulfonyurea Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orallly, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Suflonylurea
Status: Archived
Updated: 1/1/1970
9.197.001 Boehringer Ingelheim Investigational Site
mi
from
Tempe, AZ
Efficacy and Safety Study With BI 10773 vs. Placebo as add-on to Metformin or Metformin Plus Sulfonyurea Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orallly, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Suflonylurea
Status: Archived
1245.25.10058 Boehringer Ingelheim Investigational Site
mi
from
Huntington Park, CA
Efficacy and Safety Study With BI 10773 vs. Placebo as add-on to Metformin or Metformin Plus Sulfonyurea Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orallly, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Suflonylurea
Status: Archived
Updated: 1/1/1970
1245.25.10058 Boehringer Ingelheim Investigational Site
mi
from
Huntington Park, CA
Efficacy and Safety Study With BI 10773 vs. Placebo as add-on to Metformin or Metformin Plus Sulfonyurea Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orallly, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Suflonylurea
Status: Archived
Boehringer Ingelheim Investigational Site
mi
from
Los Angeles, CA
Efficacy and Safety Study With BI 10773 vs. Placebo as add-on to Metformin or Metformin Plus Sulfonyurea Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orallly, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Suflonylurea
Status: Archived
Updated: 1/1/1970
Boehringer Ingelheim Investigational Site
mi
from
Los Angeles, CA
Efficacy and Safety Study With BI 10773 vs. Placebo as add-on to Metformin or Metformin Plus Sulfonyurea Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orallly, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Suflonylurea
Status: Archived
205.452.01089 Boehringer Ingelheim Investigational Site
mi
from
Rancho Cucamonga, CA
Efficacy and Safety Study With BI 10773 vs. Placebo as add-on to Metformin or Metformin Plus Sulfonyurea Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orallly, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Suflonylurea
Status: Archived
Updated: 1/1/1970
205.452.01089 Boehringer Ingelheim Investigational Site
mi
from
Rancho Cucamonga, CA
Efficacy and Safety Study With BI 10773 vs. Placebo as add-on to Metformin or Metformin Plus Sulfonyurea Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orallly, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Suflonylurea
Status: Archived
205.452.01109 Boehringer Ingelheim Investigational Site
mi
from
Waterbury, CT
Efficacy and Safety Study With BI 10773 vs. Placebo as add-on to Metformin or Metformin Plus Sulfonyurea Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orallly, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Suflonylurea
Status: Archived
Updated: 1/1/1970
205.452.01109 Boehringer Ingelheim Investigational Site
mi
from
Waterbury, CT
Efficacy and Safety Study With BI 10773 vs. Placebo as add-on to Metformin or Metformin Plus Sulfonyurea Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orallly, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Suflonylurea
Status: Archived
1245.23.10042 Boehringer Ingelheim Investigational Site
mi
from
Fort Lauderdale, FL
Efficacy and Safety Study With BI 10773 vs. Placebo as add-on to Metformin or Metformin Plus Sulfonyurea Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orallly, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Suflonylurea
Status: Archived
Updated: 1/1/1970
1245.23.10042 Boehringer Ingelheim Investigational Site
mi
from
Fort Lauderdale, FL
Efficacy and Safety Study With BI 10773 vs. Placebo as add-on to Metformin or Metformin Plus Sulfonyurea Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orallly, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Suflonylurea
Status: Archived
205.452.01184 Boehringer Ingelheim Investigational Site
mi
from
Jupiter, FL
Efficacy and Safety Study With BI 10773 vs. Placebo as add-on to Metformin or Metformin Plus Sulfonyurea Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orallly, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Suflonylurea
Status: Archived
Updated: 1/1/1970
205.452.01184 Boehringer Ingelheim Investigational Site
mi
from
Jupiter, FL
Efficacy and Safety Study With BI 10773 vs. Placebo as add-on to Metformin or Metformin Plus Sulfonyurea Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orallly, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Suflonylurea
Status: Archived
Boehringer Ingelheim Investigational Site
mi
from
Miami, FL
Efficacy and Safety Study With BI 10773 vs. Placebo as add-on to Metformin or Metformin Plus Sulfonyurea Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orallly, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Suflonylurea
Status: Archived
Updated: 1/1/1970
Boehringer Ingelheim Investigational Site
mi
from
Miami, FL
Efficacy and Safety Study With BI 10773 vs. Placebo as add-on to Metformin or Metformin Plus Sulfonyurea Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orallly, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Suflonylurea
Status: Archived
1218.64.10016 Boehringer Ingelheim Investigational Site
mi
from
Decatur, GA
Efficacy and Safety Study With BI 10773 vs. Placebo as add-on to Metformin or Metformin Plus Sulfonyurea Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orallly, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Suflonylurea
Status: Archived
Updated: 1/1/1970
1218.64.10016 Boehringer Ingelheim Investigational Site
mi
from
Decatur, GA
Efficacy and Safety Study With BI 10773 vs. Placebo as add-on to Metformin or Metformin Plus Sulfonyurea Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orallly, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Suflonylurea
Status: Archived
Boehringer Ingelheim Investigational Site
mi
from
Chicago, IL
Efficacy and Safety Study With BI 10773 vs. Placebo as add-on to Metformin or Metformin Plus Sulfonyurea Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orallly, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Suflonylurea
Status: Archived
Updated: 1/1/1970
Boehringer Ingelheim Investigational Site
mi
from
Chicago, IL
Efficacy and Safety Study With BI 10773 vs. Placebo as add-on to Metformin or Metformin Plus Sulfonyurea Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orallly, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Suflonylurea
Status: Archived
1245.23.10159 Boehringer Ingelheim Investigational Site
mi
from
Des Moines, IA
Efficacy and Safety Study With BI 10773 vs. Placebo as add-on to Metformin or Metformin Plus Sulfonyurea Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orallly, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Suflonylurea
Status: Archived
Updated: 1/1/1970
1245.23.10159 Boehringer Ingelheim Investigational Site
mi
from
Des Moines, IA
Efficacy and Safety Study With BI 10773 vs. Placebo as add-on to Metformin or Metformin Plus Sulfonyurea Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orallly, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Suflonylurea
Status: Archived
1245.23.10117 Boehringer Ingelheim Investigational Site
mi
from
Arkansas City, KA
Efficacy and Safety Study With BI 10773 vs. Placebo as add-on to Metformin or Metformin Plus Sulfonyurea Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orallly, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Suflonylurea
Status: Archived
Updated: 1/1/1970
1245.23.10117 Boehringer Ingelheim Investigational Site
mi
from
Arkansas City, KA
Efficacy and Safety Study With BI 10773 vs. Placebo as add-on to Metformin or Metformin Plus Sulfonyurea Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orallly, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Suflonylurea
Status: Archived
1245.23.10157 Boehringer Ingelheim Investigational Site
mi
from
Newton, KA
Efficacy and Safety Study With BI 10773 vs. Placebo as add-on to Metformin or Metformin Plus Sulfonyurea Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orallly, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Suflonylurea
Status: Archived
Updated: 1/1/1970
1245.23.10157 Boehringer Ingelheim Investigational Site
mi
from
Newton, KA
Efficacy and Safety Study With BI 10773 vs. Placebo as add-on to Metformin or Metformin Plus Sulfonyurea Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orallly, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Suflonylurea
Status: Archived
1245.23.10148 Boehringer Ingelheim Investigational Site
mi
from
Lexington, KY
Efficacy and Safety Study With BI 10773 vs. Placebo as add-on to Metformin or Metformin Plus Sulfonyurea Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orallly, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Suflonylurea
Status: Archived
Updated: 1/1/1970
1245.23.10148 Boehringer Ingelheim Investigational Site
mi
from
Lexington, KY
Efficacy and Safety Study With BI 10773 vs. Placebo as add-on to Metformin or Metformin Plus Sulfonyurea Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orallly, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Suflonylurea
Status: Archived
1245.23.10160 Boehringer Ingelheim Investigational Site
mi
from
Essex, MD
Efficacy and Safety Study With BI 10773 vs. Placebo as add-on to Metformin or Metformin Plus Sulfonyurea Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orallly, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Suflonylurea
Status: Archived
Updated: 1/1/1970
1245.23.10160 Boehringer Ingelheim Investigational Site
mi
from
Essex, MD
Efficacy and Safety Study With BI 10773 vs. Placebo as add-on to Metformin or Metformin Plus Sulfonyurea Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orallly, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Suflonylurea
Status: Archived
1218.61.01052 Boehringer Ingelheim Investigational Site
mi
from
Las Vegas, NV
Efficacy and Safety Study With BI 10773 vs. Placebo as add-on to Metformin or Metformin Plus Sulfonyurea Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orallly, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Suflonylurea
Status: Archived
Updated: 1/1/1970
1218.61.01052 Boehringer Ingelheim Investigational Site
mi
from
Las Vegas, NV
Efficacy and Safety Study With BI 10773 vs. Placebo as add-on to Metformin or Metformin Plus Sulfonyurea Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orallly, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Suflonylurea
Status: Archived
1200.32.2603 Boehringer Ingelheim Investigational Site
mi
from
Rochester, NY
Efficacy and Safety Study With BI 10773 vs. Placebo as add-on to Metformin or Metformin Plus Sulfonyurea Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orallly, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Suflonylurea
Status: Archived
Updated: 1/1/1970
1200.32.2603 Boehringer Ingelheim Investigational Site
mi
from
Rochester, NY
Efficacy and Safety Study With BI 10773 vs. Placebo as add-on to Metformin or Metformin Plus Sulfonyurea Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orallly, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Suflonylurea
Status: Archived
1245.23.10123 Boehringer Ingelheim Investigational Site
mi
from
Smithtown, NY
Efficacy and Safety Study With BI 10773 vs. Placebo as add-on to Metformin or Metformin Plus Sulfonyurea Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orallly, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Suflonylurea
Status: Archived
Updated: 1/1/1970
1245.23.10123 Boehringer Ingelheim Investigational Site
mi
from
Smithtown, NY
Efficacy and Safety Study With BI 10773 vs. Placebo as add-on to Metformin or Metformin Plus Sulfonyurea Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orallly, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Suflonylurea
Status: Archived
1199.15.10029 Boehringer Ingelheim Investigational Site
mi
from
Cleveland, OH
Efficacy and Safety Study With BI 10773 vs. Placebo as add-on to Metformin or Metformin Plus Sulfonyurea Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orallly, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Suflonylurea
Status: Archived
Updated: 1/1/1970
1199.15.10029 Boehringer Ingelheim Investigational Site
mi
from
Cleveland, OH
Efficacy and Safety Study With BI 10773 vs. Placebo as add-on to Metformin or Metformin Plus Sulfonyurea Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orallly, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Suflonylurea
Status: Archived
Boehringer Ingelheim Investigational Site
mi
from
Columbus, OH
Efficacy and Safety Study With BI 10773 vs. Placebo as add-on to Metformin or Metformin Plus Sulfonyurea Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orallly, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Suflonylurea
Status: Archived
Updated: 1/1/1970
Boehringer Ingelheim Investigational Site
mi
from
Columbus, OH
Efficacy and Safety Study With BI 10773 vs. Placebo as add-on to Metformin or Metformin Plus Sulfonyurea Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orallly, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Suflonylurea
Status: Archived
Boehringer Ingelheim Investigational Site
mi
from
Oklahoma City, OK
Efficacy and Safety Study With BI 10773 vs. Placebo as add-on to Metformin or Metformin Plus Sulfonyurea Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orallly, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Suflonylurea
Status: Archived
Updated: 1/1/1970
Boehringer Ingelheim Investigational Site
mi
from
Oklahoma City, OK
Efficacy and Safety Study With BI 10773 vs. Placebo as add-on to Metformin or Metformin Plus Sulfonyurea Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orallly, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Suflonylurea
Status: Archived
1245.23.10158 Boehringer Ingelheim Investigational Site
mi
from
Mt Pleasant, SC
Efficacy and Safety Study With BI 10773 vs. Placebo as add-on to Metformin or Metformin Plus Sulfonyurea Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orallly, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Suflonylurea
Status: Archived
Updated: 1/1/1970
1245.23.10158 Boehringer Ingelheim Investigational Site
mi
from
Mt Pleasant, SC
Efficacy and Safety Study With BI 10773 vs. Placebo as add-on to Metformin or Metformin Plus Sulfonyurea Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orallly, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Suflonylurea
Status: Archived
1218.61.01017 Boehringer Ingelheim Investigational Site
mi
from
Simpsonville, SC
Efficacy and Safety Study With BI 10773 vs. Placebo as add-on to Metformin or Metformin Plus Sulfonyurea Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orallly, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Suflonylurea
Status: Archived
Updated: 1/1/1970
1218.61.01017 Boehringer Ingelheim Investigational Site
mi
from
Simpsonville, SC
Efficacy and Safety Study With BI 10773 vs. Placebo as add-on to Metformin or Metformin Plus Sulfonyurea Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orallly, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Suflonylurea
Status: Archived
Boehringer Ingelheim Investigational Site
mi
from
Houston, TX
Efficacy and Safety Study With BI 10773 vs. Placebo as add-on to Metformin or Metformin Plus Sulfonyurea Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orallly, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Suflonylurea
Status: Archived
Updated: 1/1/1970
Boehringer Ingelheim Investigational Site
mi
from
Houston, TX
Efficacy and Safety Study With BI 10773 vs. Placebo as add-on to Metformin or Metformin Plus Sulfonyurea Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orallly, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Suflonylurea
Status: Archived
1245.23.10153 Boehringer Ingelheim Investigational Site
mi
from
Hurst, TX
Efficacy and Safety Study With BI 10773 vs. Placebo as add-on to Metformin or Metformin Plus Sulfonyurea Over 24 Weeks in Patients With Type 2 Diabetes
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orallly, Once Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Suflonylurea
Status: Archived
Updated: 1/1/1970
1245.23.10153 Boehringer Ingelheim Investigational Site
mi
from
Hurst, TX